\n\n
<\/div>\n\n\n\n\nVICTORIA is the first positive outcome study focusing specifically on over 5,000 high-risk HFrEF patients following a HF hospitalization or outpatient IV diuretic use<\/strong><\/h1><\/div>\n\n\n\n
VICTORIA is the first positive outcome study focusing specifically on over 5,000 high-risk HFrEF patients following a HF hospitalization or outpatient IV diuretic use<\/strong><\/h1><\/div>\n\n\n\n<\/div>\n\n\n\nVICTORIA: key characteristics<\/strong><\/h3><\/div>\n\n\n\n<\/div>\n\n\n\n\n<\/i><\/div>Phase 3, randomized, parallel-group, placebo-controlled, double-blind, event-driven, multicenter trial1<\/sup><\/strong><\/h4><\/div><\/div><\/div>\n\n\n\n\n
\n\n\n\n![\"\"\/](\"https:\/\/www.merckconnect.com\/verquvo\/wp-content\/uploads\/sites\/67\/2024\/02\/Group-3.svg\")
<\/picture><\/figure><\/div>Compared VERQUVO to placebo, both added on to standard of care HF therapies<\/strong><\/h4>\n\n\n- Primary endpoint was a composite of time to CV death or HF hospitalization<\/li>
- Patients were treated up to the target maintenance dose of VERQUVO 10 mg once daily or matching placebo<\/li><\/ul><\/div>\n\n<\/div><\/div><\/div><\/div>\n\n\n\n
\n\n\n\n<\/i><\/div>Median follow-up was 11 months<\/span><\/strong><\/h4><\/div><\/div><\/div>\n\n\n\n
\n\n\n\n<\/i><\/div>Included 5,050 adult patients with HFrEF:<\/strong><\/h4>\n- 84% had a HF hospitalization within 6 months of enrollment<\/li>
- 16% had been treated with a IV diuretics within 3 months of enrollment<\/li>
- High NT-proBNP levels: Median NT-proBNP=2,800 pg\/mL2<\/sup><\/span><\/li>
- Low mean eGFR: 62 mL\/min\/1.73 m2 2<\/sup><\/span>
- 12% of patients had an eGFR between 15 and 30 mL\/min\/1.73 m2<\/sup><\/span><\/li><\/ul><\/li>
- VERQUVO was not studied in patients with eGFR <15 mL\/min\/1.73 m2<\/sup> <\/span>at treatment initiation or who were on dialysis<\/li>
- Patients were well treated: 91% of patients were treated with 2 or more HF medications <\/li>
- LVEF <45%<\/li><\/ul><\/div>\n<\/div><\/div><\/div><\/div>\n\n\n\n<\/div>\n\n\n\n
Definitions:<\/strong><\/h2><\/div>\n\n\n\nCV = cardiovascular; eGFR = estimated glomerular filtration rate; HF = heart failure; HFH = heart failure hospitalization; HFrEF = heart failure with reduced ejection fraction; IV = intravenous; LVEF = left ventricular ejection fraction; NT-proBNP = N-terminal prohormone B-type natriuretic peptide; VICTORIA = Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. <\/p>\n\n\n\n
<\/div>\n\n\n\nReferences:<\/strong><\/h2><\/div>\n\n\n\n- Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med.<\/em> 2020;382(20):1883-1893. <\/li>
- Pieske B, Patel MJ, Westerhout CM, et al; on behalf of the VICTORIA Study Group. Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial. Eur J Heart Fail.<\/em> 2019;21(12):1596-1604.<\/li><\/ol><\/div>\n<\/div><\/div><\/div>\n\n\n\n\n<\/span><\/div>
VICTORIA: key characteristics<\/strong><\/h3><\/div>\n\n\n\n<\/div>\n\n\n\n\n<\/i><\/div>Phase 3, randomized, parallel-group, placebo-controlled, double-blind, event-driven, multicenter trial1<\/sup><\/strong><\/h4><\/div><\/div><\/div>\n\n\n\n\n
\n\n\n\n<\/picture><\/figure><\/div>Compared VERQUVO to placebo, both added on to standard of care HF therapies<\/strong><\/h4>\n\n\n- Primary endpoint was a composite of time to CV death or HF hospitalization<\/li>
- Patients were treated up to the target maintenance dose of VERQUVO 10 mg once daily or matching placebo<\/li><\/ul><\/div>\n\n<\/div><\/div><\/div><\/div>\n\n\n\n
\n\n\n\n<\/i><\/div>Median follow-up was 11 months<\/span><\/strong><\/h4><\/div><\/div><\/div>\n\n\n\n
\n\n\n\n<\/i><\/div>Included 5,050 adult patients with HFrEF:<\/strong><\/h4>\n- 84% had a HF hospitalization within 6 months of enrollment<\/li>
- 16% had been treated with a IV diuretics within 3 months of enrollment<\/li>
- High NT-proBNP levels: Median NT-proBNP=2,800 pg\/mL2<\/sup><\/span><\/li>
- Low mean eGFR: 62 mL\/min\/1.73 m2 2<\/sup><\/span>
- 12% of patients had an eGFR between 15 and 30 mL\/min\/1.73 m2<\/sup><\/span><\/li><\/ul><\/li>
- VERQUVO was not studied in patients with eGFR <15 mL\/min\/1.73 m2<\/sup> <\/span>at treatment initiation or who were on dialysis<\/li>
- Patients were well treated: 91% of patients were treated with 2 or more HF medications <\/li>
- LVEF <45%<\/li><\/ul><\/div>\n<\/div><\/div><\/div><\/div>\n\n\n\n<\/div>\n\n\n\n
Definitions:<\/strong><\/h2><\/div>\n\n\n\nCV = cardiovascular; eGFR = estimated glomerular filtration rate; HF = heart failure; HFH = heart failure hospitalization; HFrEF = heart failure with reduced ejection fraction; IV = intravenous; LVEF = left ventricular ejection fraction; NT-proBNP = N-terminal prohormone B-type natriuretic peptide; VICTORIA = Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. <\/p>\n\n\n\n
<\/div>\n\n\n\nReferences:<\/strong><\/h2><\/div>\n\n\n\n- Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med.<\/em> 2020;382(20):1883-1893. <\/li>
- Pieske B, Patel MJ, Westerhout CM, et al; on behalf of the VICTORIA Study Group. Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial. Eur J Heart Fail.<\/em> 2019;21(12):1596-1604.<\/li><\/ol><\/div>\n<\/div><\/div><\/div>\n\n\n\n\n<\/span><\/div>
<\/i><\/div>Phase 3, randomized, parallel-group, placebo-controlled, double-blind, event-driven, multicenter trial1<\/sup><\/strong><\/h4><\/div><\/div><\/div>\n\n\n\n\n
Phase 3, randomized, parallel-group, placebo-controlled, double-blind, event-driven, multicenter trial1<\/sup><\/strong><\/h4><\/div><\/div><\/div>\n\n\n\n\n
\n\n\n\n<\/picture><\/figure><\/div>Compared VERQUVO to placebo, both added on to standard of care HF therapies<\/strong><\/h4>\n\n\n- Primary endpoint was a composite of time to CV death or HF hospitalization<\/li>
- Patients were treated up to the target maintenance dose of VERQUVO 10 mg once daily or matching placebo<\/li><\/ul><\/div>\n\n<\/div><\/div><\/div><\/div>\n\n\n\n
\n\n\n\n<\/i><\/div>Median follow-up was 11 months<\/span><\/strong><\/h4><\/div><\/div><\/div>\n\n\n\n
\n\n\n\n<\/i><\/div>Included 5,050 adult patients with HFrEF:<\/strong><\/h4>\n- 84% had a HF hospitalization within 6 months of enrollment<\/li>
- 16% had been treated with a IV diuretics within 3 months of enrollment<\/li>
- High NT-proBNP levels: Median NT-proBNP=2,800 pg\/mL2<\/sup><\/span><\/li>
- Low mean eGFR: 62 mL\/min\/1.73 m2 2<\/sup><\/span>
- 12% of patients had an eGFR between 15 and 30 mL\/min\/1.73 m2<\/sup><\/span><\/li><\/ul><\/li>
- VERQUVO was not studied in patients with eGFR <15 mL\/min\/1.73 m2<\/sup> <\/span>at treatment initiation or who were on dialysis<\/li>
- Patients were well treated: 91% of patients were treated with 2 or more HF medications <\/li>
- LVEF <45%<\/li><\/ul><\/div>\n<\/div><\/div><\/div><\/div>\n\n\n\n<\/div>\n\n\n\n
Definitions:<\/strong><\/h2><\/div>\n\n\n\nCV = cardiovascular; eGFR = estimated glomerular filtration rate; HF = heart failure; HFH = heart failure hospitalization; HFrEF = heart failure with reduced ejection fraction; IV = intravenous; LVEF = left ventricular ejection fraction; NT-proBNP = N-terminal prohormone B-type natriuretic peptide; VICTORIA = Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. <\/p>\n\n\n\n
<\/div>\n\n\n\nReferences:<\/strong><\/h2><\/div>\n\n\n\n- Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med.<\/em> 2020;382(20):1883-1893. <\/li>
- Pieske B, Patel MJ, Westerhout CM, et al; on behalf of the VICTORIA Study Group. Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial. Eur J Heart Fail.<\/em> 2019;21(12):1596-1604.<\/li><\/ol><\/div>\n<\/div><\/div><\/div>\n\n\n\n\n<\/span><\/div>
<\/picture><\/figure><\/div>Compared VERQUVO to placebo, both added on to standard of care HF therapies<\/strong><\/h4>\n\n\n- Primary endpoint was a composite of time to CV death or HF hospitalization<\/li>
- Patients were treated up to the target maintenance dose of VERQUVO 10 mg once daily or matching placebo<\/li><\/ul><\/div>\n\n<\/div><\/div><\/div><\/div>\n\n\n\n
\n\n\n\n<\/i><\/div>Median follow-up was 11 months<\/span><\/strong><\/h4><\/div><\/div><\/div>\n\n\n\n
\n\n\n\n<\/i><\/div>Included 5,050 adult patients with HFrEF:<\/strong><\/h4>\n- 84% had a HF hospitalization within 6 months of enrollment<\/li>
- 16% had been treated with a IV diuretics within 3 months of enrollment<\/li>
- High NT-proBNP levels: Median NT-proBNP=2,800 pg\/mL2<\/sup><\/span><\/li>
- Low mean eGFR: 62 mL\/min\/1.73 m2 2<\/sup><\/span>
- 12% of patients had an eGFR between 15 and 30 mL\/min\/1.73 m2<\/sup><\/span><\/li><\/ul><\/li>
- VERQUVO was not studied in patients with eGFR <15 mL\/min\/1.73 m2<\/sup> <\/span>at treatment initiation or who were on dialysis<\/li>
- Patients were well treated: 91% of patients were treated with 2 or more HF medications <\/li>
- LVEF <45%<\/li><\/ul><\/div>\n<\/div><\/div><\/div><\/div>\n\n\n\n<\/div>\n\n\n\n
Definitions:<\/strong><\/h2><\/div>\n\n\n\nCV = cardiovascular; eGFR = estimated glomerular filtration rate; HF = heart failure; HFH = heart failure hospitalization; HFrEF = heart failure with reduced ejection fraction; IV = intravenous; LVEF = left ventricular ejection fraction; NT-proBNP = N-terminal prohormone B-type natriuretic peptide; VICTORIA = Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. <\/p>\n\n\n\n
<\/div>\n\n\n\nReferences:<\/strong><\/h2><\/div>\n\n\n\n- Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med.<\/em> 2020;382(20):1883-1893. <\/li>
- Pieske B, Patel MJ, Westerhout CM, et al; on behalf of the VICTORIA Study Group. Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial. Eur J Heart Fail.<\/em> 2019;21(12):1596-1604.<\/li><\/ol><\/div>\n<\/div><\/div><\/div>\n\n\n\n\n<\/span><\/div>
- Primary endpoint was a composite of time to CV death or HF hospitalization<\/li>
- Patients were treated up to the target maintenance dose of VERQUVO 10 mg once daily or matching placebo<\/li><\/ul><\/div>\n\n<\/div><\/div><\/div><\/div>\n\n\n\n
\n\n\n\n<\/i><\/div>Median follow-up was 11 months<\/span><\/strong><\/h4><\/div><\/div><\/div>\n\n\n\n
\n\n\n\n<\/i><\/div>Included 5,050 adult patients with HFrEF:<\/strong><\/h4>
\n- 84% had a HF hospitalization within 6 months of enrollment<\/li>
- 16% had been treated with a IV diuretics within 3 months of enrollment<\/li>
- High NT-proBNP levels: Median NT-proBNP=2,800 pg\/mL2<\/sup><\/span><\/li>
- Low mean eGFR: 62 mL\/min\/1.73 m2 2<\/sup><\/span>
- 12% of patients had an eGFR between 15 and 30 mL\/min\/1.73 m2<\/sup><\/span><\/li><\/ul><\/li>
- VERQUVO was not studied in patients with eGFR <15 mL\/min\/1.73 m2<\/sup> <\/span>at treatment initiation or who were on dialysis<\/li>
- Patients were well treated: 91% of patients were treated with 2 or more HF medications <\/li>
- LVEF <45%<\/li><\/ul><\/div>\n<\/div><\/div><\/div><\/div>\n\n\n\n
<\/div>\n\n\n\nDefinitions:<\/strong><\/h2><\/div>\n\n\n\n
CV = cardiovascular; eGFR = estimated glomerular filtration rate; HF = heart failure; HFH = heart failure hospitalization; HFrEF = heart failure with reduced ejection fraction; IV = intravenous; LVEF = left ventricular ejection fraction; NT-proBNP = N-terminal prohormone B-type natriuretic peptide; VICTORIA = Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. <\/p>\n\n\n\n
<\/div>\n\n\n\nReferences:<\/strong><\/h2><\/div>\n\n\n\n
- Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med.<\/em> 2020;382(20):1883-1893. <\/li>
- Pieske B, Patel MJ, Westerhout CM, et al; on behalf of the VICTORIA Study Group. Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial. Eur J Heart Fail.<\/em> 2019;21(12):1596-1604.<\/li><\/ol><\/div>\n<\/div><\/div><\/div>\n\n\n\n\n
<\/span><\/div> - Pieske B, Patel MJ, Westerhout CM, et al; on behalf of the VICTORIA Study Group. Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial. Eur J Heart Fail.<\/em> 2019;21(12):1596-1604.<\/li><\/ol><\/div>\n<\/div><\/div><\/div>\n\n\n\n\n
- VERQUVO was not studied in patients with eGFR <15 mL\/min\/1.73 m2<\/sup> <\/span>at treatment initiation or who were on dialysis<\/li>
- Low mean eGFR: 62 mL\/min\/1.73 m2 2<\/sup><\/span>